A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease
Not Applicable
Recruiting
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Diagnostic Test: SpirometryDiagnostic Test: Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)Diagnostic Test: Magnetic Resonance ImagingDiagnostic Test: Chest Computer TomographyDiagnostic Test: Blood biomarker analysis
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT05492994
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 66
- Registration Number
- NCT05471856
- Locations
- 🇯🇵
Saitama Medical University International Medical Center, Saitama, Hidaka, Japan
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT05469646
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT05467475
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Dipeptidyl Peptidate-4 inhibitors
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30400
- Registration Number
- NCT05465317
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States
A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine
Phase 1
Withdrawn
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05451095
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
Phase 1
Terminated
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2
- Registration Number
- NCT05446129
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 62
- Registration Number
- NCT05440799
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 1015550 ICFDrug: BI 1015550 TF2
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT05428436
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 456906 (C-14)
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT05421338
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
© Copyright 2025. All Rights Reserved by MedPath